Please login to the form below
pricing
This page shows the latest pricing news and features for those working in and with pharma, biotech and healthcare.
J&J inks $1bn deal with US for coronavirus vaccine
J&J has committed to providing its vaccine on a not-for-profit basis, whereas some of its competitors are seeking to recoup on their investments by pricing their candidates for
Latest news
-
Moderna looks to price COVID-19 vaccine at $50-$60 per course
Shines spotlight on pricing strategies for potential vaccines. COVID-19 vaccine frontrunner Moderna is allegedly looking to price its candidate at around $50-$60 per course, according to a report from ... According to the report, Moderna’s proposed
-
UPDATED: Gilead drops remdesivir’s orphan drug designation
This action by Gilead is Big Pharma profiteering at its finest, and shows why we cannot depend on drug companies to show responsible restraint in pricing even in a global emergency,”
-
Lilly partners with Indiana State Health Department for coronavirus testing
The US government has come under criticism for its COVID-19 testing strategy, with many citing the lack of clarity around pricing for tests as helping the spread of the virus
-
Lilly joins new Medicare scheme to reduce insulin prices
New model will cover seniors enrolled in Medicare Part D
-
Alnylam scores EU approval for RNAi drug Givlaari
Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar pricing strategy.
More from news
Approximately 107 fully matching, plus 892 partially matching documents found.
Latest Intelligence
-
The impact of COVID-19 on clinical trials
The impact of the pandemic on clinical trials is likely to be felt on a policy level, including in drug pricing negotiations. ... In addition, shifting priorities in health spending may decrease payers’ willingness to reimburse for some products and
-
Addressing the payer-regulator evidence gap in early-stage cancer
Jason Ward is Head of Haematology and Group Director, Strategy, Policy &Operations, Oncology Market Access and Pricing at AstraZeneca.
-
Health trust in a COVID-19 world – a unique opportunity for pharma
hospital strike, increasing anti-vaccination sentiment and ongoing debate about drug pricing and the cost of health innovation.
-
Risks, reforms and rewards: the evolving Russian healthcare market
However, efforts to increase state control of drug pricing and pressure to manufacture medicines locally could prove a challenge for international drug companies.
-
Cortellis Drugs to Watch in 2020 report
It faces multiple competitors across both oral and injectable therapies, as well as a stiff pricing environment due to the presence of generics and biosimilars. ... Even with a relatively low worldwide prevalence of about 400, 000 patients, haemophilia A
More from intelligence
Approximately 16 fully matching, plus 179 partially matching documents found.
Latest appointments
-
New faces at Lucid Group and ZPB Associates
Most recently, she worked in the consultancy’s rare diseases division, where is provided crisis management support in pricing/access barriers for an orphan drug.
-
New faces at Prime Global, Swordfish Advertising and Wilmington Healthcare
Both O’Leary and Massey have experience of delivering evidence-based pricing and market access communications to help build global brands.
-
New faces at GCI Health, Porterhouse Medical and Research Partnership
Meanwhile Emma Warburton joins the agency as business development executive after previously working as a pricing and market research analyst.
-
BMS appoints new commercial leader, Davies joins Eisai and more
She will also oversee marketing, pricing, forecasting and analytics. Brian Hoffmann, president of Hikma’s generics division, said: “I am looking forward to working closely with Kristy and her team to
-
Weekly comms appointments
Pyati’s new domain will see him grow and expand the group’s scientific and medical communications practice and integrating it with the firm’s analytics, digital and value, pricing and
More from appointments
Approximately 2 fully matching, plus 31 partially matching documents found.
Latest from PMHub
-
Meet OPEN Health and Pharmerit Experts at the World Pharma Pricing Market Access and Evidence Congress 2020
Join OPEN Health and Pharmerit – an OPEN Health Company at the World Pharma Pricing Market Access and Evidence Congress from 23 – 25 September 2020, as we present:.
-
Case study
Using qualitative conjoint to assess willingness-to-pay. Find out how we used our proprietary ChoiceQual conjoint technique to assess and develop a market access and pricing strategy for an influenza
-
EU Pharmaceutical Strategy Roadmap
Any discussion around the Pharmaceutical Strategy will inevitably include the issue of pricing. ... And we continue to see the pricing and reimbursement challenges faced by ATMPs.
-
Webinar: How to develop an optimal value story for your product
some of the common pitfalls that experience tells can hinder pricing and market access success.
-
Article: Pricing a coronavirus vaccine
Using findings from our recent COVID-19 impact study, Market Access Directors Rachel Howard and Brett Gardiner and Consultant Suzan Serip explore the challenges of pricing a coronavirus vaccine.
More from PMHub
Approximately 22 fully matching, plus 74 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- 20 for 2020 – Five pharma companies to watch
- Leadership change within Bedrock Group
- Moderna inks R&D agreements with Vertex and Chiesi
- OPEN Health’s Digital team have won a Bronze Award at the PM Society Digital Awards 2020
- New restrictions announced as UK’s COVID-19 alert level is increased
- Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer
- AZ/Merck's Lynparza improves survival in certain prostate cancers
- The flexible salesforce
- Navigating engagement and remote working during the pandemic
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
Quick links
Infographics
